MCL3001(RAY)试验中接受伊布替尼或替西罗莫司治疗的复发或难治性套细胞淋巴瘤患者的结局分子决定因素
基于MCL3001(RAY)III期试验中复发或难治性套细胞淋巴瘤患者的残留存档材料,分析基因表达和靶向基因测序。MCL35增殖检测在此新型药物队列中确认预后价值,优于简化MCL国际预后指数,并捕获MYC高表达、母细胞样形态、TP53异常和CCND1 3'非翻译区截短所赋予的风险。BIRC3突变/缺失和染色体8p23.3缺失对生存有负面影响;在TP53缺失/改变的患者中,伊布替尼似乎消除了不良影响。
要点
- MCL35增殖检测在伊布替尼或替西罗莫司治疗的复发/难治性套细胞淋巴瘤中确认预后价值,优于简化MCL国际预后指数。
- 无论治疗组,MCL35捕获MYC高表达、母细胞样形态、TP53异常和CCND1 3'非翻译区截短所赋予的风险。
- BIRC3突变/缺失和染色体8p23.3缺失对结局有负面影响;在TP53缺失/改变患者中伊布替尼似乎消除不良影响。
核心结论
- MCL35增殖检测在MCL3001(RAY)队列中确认预后价值,优于简化MCL国际预后指数。
- 该检测捕获MYC高表达、母细胞样形态、TP53异常和CCND1 3'非翻译区截短所赋予的风险,与治疗组无关。
- BIRC3突变/缺失和染色体8p23.3缺失对结局有负面影响;局限于TP53缺失/改变患者时,伊布替尼似乎消除不良影响。
- 对常规患者样本进行预测性生物标志物分子分析具有切实指导临床实践的潜力。
研究设计与样本
- 利用MCL3001(RAY)III期临床试验中复发或难治性套细胞淋巴瘤患者的残留存档材料,进行基因表达和靶向基因测序分析。
- 该III期临床试验将复发或难治性套细胞淋巴瘤患者随机分配至伊布替尼或替西罗莫司治疗组。
主要发现
- MCL35增殖检测在新型药物队列中确认预后价值,在区分不同结局患者方面优于简化MCL国际预后指数。
- 无论治疗组,MCL35检测捕获MYC高表达、母细胞样形态、TP53异常和CCND1 3'非翻译区截短所赋予的风险。
- BIRC3突变/缺失对结局有负面影响;染色体8p23.3缺失也对生存有负面影响。
- 局限于TP53缺失/改变患者,伊布替尼似乎消除对结局的不良影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is a rare, incurable lymphoma subtype characterized by heterogeneous outcomes. To better understand the clinical behavior and response to treatment, predictive biomarkers are needed. Using residual archived material from patients enrolled in the MCL3001 (RAY) study, we performed detailed analyses of gene expression and targeted genetic sequencing. This phase III clinical trial randomized patients with relapsed or refractory MCL to treatment with either ibrutinib or temsirolimus. We confirmed the prognostic capability of the gene expression proliferation assay MCL35 in this cohort treated with novel agents; it outperformed the simplified MCL International Prognostic Index in discriminating patients with different outcomes. Regardless of treatment arm, our data demonstrated that this assay captures the risk conferred by known biological factors, including increased MYC expression, blastoid morphology, aberrations of TP53, and truncated CCND1 3' untranslated region. We showed the negative impact of BIRC3 mutations/deletions on outcomes in this cohort and identified that deletion of chromosome 8p23.3 also negatively impacts survival. Restricted to patients with deletions/alterations in TP53, ibrutinib appeared to abrogate the deleterious impact on outcome. These data illustrate the potential to perform a molecular analysis of predictive biomarkers on routine patient samples that can meaningfully inform clinical practice.
引用
- Freeman CL, Pararajalingam P, Jin L, et al. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial. Leukemia. 2022. PMID: 35963941. doi:10.1038/s41375-022-01658-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。